Term ends Dec 9, 2026 · High confidence
20-year base term ended Nov 15, 2024
Held by Synergetics, Inc.
Filed Oct 26, 2006 as application 10/586,018 · Granted Jun 12, 2012
Base term plus 754 days of patent term adjustment (USPTO delay)
Today
2004
2026
Clock starts
Nov 15, 2004
Nov 15, 2004
Term ends
Dec 9, 2026
Dec 9, 2026
Granted
Jun 12, 2012
Jun 12, 2012
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
754
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
24
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 754 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 15, 2004, when application PCT/US2004/038175, the earliest non-provisional in its chain, was filed (this one was filed Oct 26, 2006) | Nov 15, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +754 days, USPTO patent term adjustment record | Dec 9, 2026 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 9, 2026 | High confidence |
This family
| US 6,772,765 | Term ended Jul 2022 | Jul 2022 |
| US 6,984,230 | Term ended Apr 2020 | Apr 2020 |
| US 7,470,269 | Term ended Jul 2025 | Jul 2025 |
| Application PCT/US2004/009115 | PCT application no patent term | no patent term |
| US 8,241,321 | In force Feb 2030 | Feb 2030 |
| Application PCT/US2004/038176 | PCT application no patent term | no patent term |
| Application PCT/US2004/038175 | PCT application no patent term | no patent term |
| US 7,402,158 | Term ended Dec 2020 | Dec 2020 |
8 of 24 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
The 40 most recent of 43 recorded documents are shown; the 3 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 21, 2015 Reel 37357, frame 490 | Sprout Pharmaceuticals, Inc., as Grantor; Unilens Vision Inc., as Grantor; Commonwealth Laboratories, LLC, as Grantor; Synergetics USA, Inc., as Grantor | Barclays Bank PLC, as Collateral Agent | Security Agreement |
| Mar 11, 2019 Reel 48556, frame 758 | Bausch Health Americas, Inc.; Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc. | The Bank of New York Mellon, as Notes Collateral Agent | Security Interest |
| Apr 8, 2025 Reel 70778, frame 199 | Barclays Bank PLC, as Collateral Agent | Solta Medical, Inc.; Precision Dermatology, Inc.; Bausch Health Ireland Limited (F/K/A/ Valeant Pharmaceuticals Ireland Limited); Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Medicis Pharmaceutical Corporation; Humax Pharmaceutical S.A.; Solta Medical Ireland Limited; Bausch & Lomb Mexico, S.A. de C.V.; Bausch+lomb Ops B.V.; Bausch Health Americas, Inc.; Bausch Health Companies Inc.; Bausch Health Holdco Limited; Bausch Health Magyarorszag KFT (A/K/A Bausch Health Hungary LLC); Bausch Health Poland Spolka Z Ograniczona Odpowiedzialnoscia (F/K/A Valeant Pharma Poland Spolka Z Ograniczona Odpowiedzialnoscia); Bausch Health US, LLC; Bausch Health, Canada Inc. / Sante Bausch, Canada Inc.; ICN Polfa Rzeszow Spolka Akcyjna (A/K/A ICN Polfa Rzeszow S.A.); Orapharma, Inc.; Przedsiebiorstwo Farmaceutyczne Jelfa Spolka Akcyjna (A/K/A Przedsiebiorstwo Farmaceutyczne Jelfa S.A.); Solta Medical Dutch Holdings B.V.; V-Bac Holding Corp.; VRX Holdco LLC; 1261229 B.C. Ltd.; 1530065 B.C. Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Ireland Limited (F/K/A/ Valeant Pharmaceuticals Ireland Limited) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Humax Pharmaceutical S.A. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical Ireland Limited | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch & Lomb Mexico, S.A. de C.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch+lomb Ops B.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Americas, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Companies Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Holdco Limited | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Magyarorszag KFT (A/K/A Bausch Health Hungary LLC) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health Poland Spolka Z Ograniczona Odpowiedzialnoscia (F/K/A Valeant Pharma Poland Spolka Z Ograniczona Odpowiedzialnoscia) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health US, LLC | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health, Canada Inc. / Sante Bausch, Canada Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | ICN Polfa Rzeszow Spolka Akcyjna (A/K/A ICN Polfa Rzeszow S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Przedsiebiorstwo Farmaceutyczne Jelfa Spolka Akcyjna (A/K/A Przedsiebiorstwo Farmaceutyczne Jelfa S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical Dutch Holdings B.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | V-Bac Holding Corp. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | VRX Holdco LLC | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1261229 B.C. Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1530065 B.C. Ltd. | Release of Security Interest |
| Nov 20, 2025 Reel 73637, frame 126 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Americas, Inc.; Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health US, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2026
Term ends Dec 9, 2026. No further fees fall due before then
Note
The 754 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
159
later US patents cite this one
That is top 5% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.